PROSpect's factorial RCT found no benefit from prone positioning or HFOV in moderate-to-severe PARDS, forcing a reckoning with two...
RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology trials must...
J&J's icotrokinra hit every UC endpoint in NEJM's Oct 2026 data, and the trial design choices behind that success...
FDA's approval of two blood-based Alzheimer's tests signals regulators now accept plasma biomarkers as primary endpoints, reshaping CNS trial...
Only 12% of ~4,000 clinical prediction model studies share code, per Nature Medicine. FDA and NIH mandates exist, but...
A double-blind tACS trial targeting theta oscillations in methamphetamine patients sets a new design standard regulators will use to...
Evorpacept's Phase 2 data in HER2+ gastric cancer reveals a CD47 biomarker selection gap that could reshape how oncology...
FDA finalized its psychedelic drug guidance July 14, 2026. COMPASS, Usona, and MAPS now face blinding failures, DEA barriers,...
Nature Medicine's Validation Accords push for a generative AI consensus framework, and expose a regulatory gap that could invalidate...
Early trial termination once signaled collapse. Now it signals design sophistication, and regulators, sponsors, and CROs need a new...
